Balancing Efficacy and Safety of IPF Treatment: Perspectives of People Living With Idiopathic Pulmonary Fibrosis (IPF). IPF Summit. 2025. Graham CS, et al. [Poster]
Previous
Previous
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
Next
Next